BMI Change During Puberty Is an Important Determinant of Adult Type 2 Diabetes Risk in Men.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 20 06 2018
accepted: 29 11 2018
pubmed: 6 12 2018
medline: 28 2 2020
entrez: 6 12 2018
Statut: ppublish

Résumé

The aim of this study was to determine the role of change in body mass index (BMI) during puberty, independent of childhood overweight, for risk of adult type 2 diabetes in men. We included 36,176 men who had weight and height measured at age 8 and 20 years available from the BMI Epidemiology Study and the Conscription register. Information on type 2 diabetes (n = 1,777) was retrieved from the Swedish National Patient Register. Hazard ratios and 95% CIs were estimated by Cox regressions including birth year and country of birth as covariates. Because the assumption of proportional hazards was violated for the association between BMI change during puberty and type 2 diabetes, we split the follow-up time into early (≤55.7 years) and late (>55.7 years). Both childhood overweight and high BMI increase during puberty associated with risk of adult type 2 diabetes. Men with childhood overweight that normalized during puberty did not have significantly increased risk of type 2 diabetes [early type 2 diabetes 1.28 (0.89; 1.82); late type 2 diabetes 1.35 (0.97; 1.87)]. Men who developed overweight during puberty [early 4.67 (3.90; 5.58); late 2.85 (2.25; 3.61)] and men overweight throughout childhood and puberty [early 4.82 (3.84; 6.05); late 3.04 (2.27; 4.06)] had substantially increased risk of type 2 diabetes compared with men who were never overweight. BMI change during puberty is an important and childhood BMI a modest independent determinant of adult type 2 diabetes risk in men.

Identifiants

pubmed: 30517677
pii: 5224761
doi: 10.1210/jc.2018-01339
pmc: PMC6456008
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1823-1832

Informations de copyright

Copyright © 2019 Endocrine Society.

Références

Am J Epidemiol. 2014 Jun 1;179(11):1353-65
pubmed: 24786797
Lancet. 2011 Feb 12;377(9765):557-67
pubmed: 21295846
Lancet Diabetes Endocrinol. 2014 Aug;2(8):648-54
pubmed: 24856161
Pediatrics. 2015 Jan;135(1):e144-51
pubmed: 25535261
Diabetes Care. 2003 Sep;26(9):2512-7
pubmed: 12941711
FEBS Lett. 2017 Oct;591(19):3061-3088
pubmed: 28677122
Obesity (Silver Spring). 2010 Nov;18(11):2191-8
pubmed: 20339361
Diabet Med. 2015 Oct;32(10):1319-28
pubmed: 25662570
Diabetes. 2009 Apr;58(4):867-74
pubmed: 19168597
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Nature. 2017 Feb 8;542(7640):177-185
pubmed: 28179656
Sci Rep. 2017 Feb 23;7:43422
pubmed: 28230104
Diabetes. 2015 Dec;64(12):4220-5
pubmed: 26253610
N Engl J Med. 2012 Oct 4;367(14):1332-40
pubmed: 23034021
Obesity (Silver Spring). 2017 May;25(5):965-971
pubmed: 28345789
Curr Opin Endocrinol Diabetes Obes. 2009 Feb;16(1):10-5
pubmed: 19115520
N Engl J Med. 2011 Apr 7;364(14):1315-25
pubmed: 21470009
N Engl J Med. 2018 Apr 05;378(14):1302-1312
pubmed: 29617589
Obesity (Silver Spring). 2013 Sep;21(9):E439-47
pubmed: 23687099
Arch Pediatr Adolesc Med. 2010 Jan;164(1):53-60
pubmed: 20048242
Vital Health Stat 11. 2002 May;(246):1-190
pubmed: 12043359
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1017-1024
pubmed: 27815089
Int J Obes (Lond). 2017 May;41(5):807-812
pubmed: 28119533
J Intern Med. 2018 Jun;283(6):558-567
pubmed: 29532534
N Engl J Med. 2011 Nov 17;365(20):1876-85
pubmed: 22087679
Int J Epidemiol. 2017 Oct 1;46(5):1400-1409
pubmed: 28338987
PLoS One. 2013 Jul 24;8(7):e70684
pubmed: 23894679
Stat Med. 1989 May;8(5):551-61
pubmed: 2657958
Neurology. 2017 Jul 25;89(4):363-369
pubmed: 28659423
Circulation. 2007 Jul 3;116(1):39-48
pubmed: 17576866
Diabetes Care. 2003 Nov;26(11):2999-3005
pubmed: 14578230
J Intern Med. 2015 Aug;278(2):219-26
pubmed: 25683182

Auteurs

Claes Ohlsson (C)

Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Maria Bygdell (M)

Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Maria Nethander (M)

Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Bioinformatics Core Facility, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Annika Rosengren (A)

Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Jenny M Kindblom (JM)

Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH